Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study aims to assess the efficacy and safety of the chemotherapy-light combination of glofitamab, polatuzumab vedotin and zanubrutinib (GPZ) in elderly patients with previously untreated diffuse large B-cell lymphoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 70 lat lub więcej
- •Potwierdzony rozpoznaniem chłoniaka z dużych komórek B typu CD20-dodatni
- •Chłoniak poddający się pomiarowi w badaniach obrazowych
- •Brak wcześniejszego leczenia chłoniaka
- •Spodziewana długość życia co najmniej 12 tygodni
- •Prawidłowa praca wątroby i nerek
- •Prawidłowe wyniki badań krwi (hemoglobina, neutrofile, płytki)
- •Pisemna zgoda na udział w badaniu
✗ Disqualifies
- •Poważne choroby serca w ostatnich 3 miesiącach (zawał, udar, zaburzenia rytmu)
- •Wysoki stopień niewydolności serca
Simplified criteria — AI translation
Trial details
- Minimum age
- 70 Years
- Last updated (source)
- October 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Zhongshan Hospital, Fudan University
Shanghai, China
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.